skip to Main Content

Expert Highlights Latest Developments in Early and Locally Advanced Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
In early and locally advanced pancreatic cancer, treatment strategies vary depending on a patient’s resectable status, and even then, it can be challenging to determine whether neoadjuvant or adjuvant therapy should be given, said Diane Simeone, MD.

“When we think about who should receive neoadjuvant therapy and has locally confined pancreatic cancer, we need to look at the resectable, borderline, and locally advanced and resectable categories,” explained Simeone, director of the Pancreatic Cancer Center at NYU Langone Health’s Perlmutter Cancer Center. Read more . . .


Back To Top